Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.

Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.

Item
http://www.wikidata.org/entity/Q36331497
Future paradigms for precision oncologyKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentIntegrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools.Biologics: the role of delivery systems in improved therapy.Assessment of the metabolism of therapeutic proteins and antibodies.Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins.Albiglutide: a unique GLP-1 receptor agonist.Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.Microdosing, isotopic labeling, radiotracers and metabolomics: relevance in drug discovery, development and safety.Dissection and Explant Culture of Murine Allantois for the In Vitro Analysis of Allantoic Attachment.Peptide-Based Supramolecular Hydrogels for Delivery of Biologics.
P2860

Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.

Item
http://www.wikidata.org/entity/Q36331497
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Challenges and opportunities i ...... dies of therapeutic biologics.
@ast
Challenges and opportunities i ...... dies of therapeutic biologics.
@en
type
label
Challenges and opportunities i ...... dies of therapeutic biologics.
@ast
Challenges and opportunities i ...... dies of therapeutic biologics.
@en
prefLabel
Challenges and opportunities i ...... dies of therapeutic biologics.
@ast
Challenges and opportunities i ...... dies of therapeutic biologics.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P6179
P698
P932
P356
P1433
P1476
Challenges and opportunities i ...... dies of therapeutic biologics.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P6179
P698
P932